American Century Companies Inc. Has $18.85 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

American Century Companies Inc. cut its holdings in shares of Glaukos Co. (NYSE:GKOS) by 62.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,281 shares of the medical instruments supplier’s stock after selling 264,285 shares during the period. American Century Companies Inc. owned about 0.32% of Glaukos worth $18,851,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Glaukos by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after acquiring an additional 72,159 shares in the last quarter. Brown Capital Management LLC grew its holdings in Glaukos by 3.4% during the fourth quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock worth $214,448,000 after buying an additional 89,420 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Glaukos by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after buying an additional 31,213 shares during the last quarter. Primecap Management Co. CA lifted its stake in Glaukos by 23.7% during the 4th quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock valued at $62,800,000 after acquiring an additional 151,415 shares in the last quarter. Finally, Iron Triangle Partners LP raised its holdings in shares of Glaukos by 75.6% in the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after purchasing an additional 184,919 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 2,250 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $121.39, for a total value of $273,127.50. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $12,362,964.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Joseph E. Gilliam sold 2,250 shares of the company’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $12,362,964.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. The disclosure for this sale can be found here. Insiders sold a total of 41,500 shares of company stock valued at $5,099,000 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Truist Financial restated a “buy” rating and set a $145.00 price target (up from $141.00) on shares of Glaukos in a report on Thursday, August 1st. Piper Sandler increased their price target on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Needham & Company LLC lifted their price objective on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus boosted their target price on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $129.82.

Glaukos Stock Down 1.8 %

Shares of NYSE GKOS opened at $127.78 on Friday. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60. The firm has a market capitalization of $6.44 billion, a price-to-earnings ratio of -44.37 and a beta of 1.03. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average of $124.89 and a 200-day moving average of $111.35.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. Sell-side analysts expect that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.